詳細検索

詳細検索

お問い合わせ

Global Ruminant Vaccines Market Outlook, InDepth Analysis & Forecast to 2032

Global Ruminant Vaccines Market Outlook, InDepth Analysis & Forecast to 2032


反芻動物用ワクチンの世界市場 2026-2032年

The global Ruminant Vaccines market is projected to grow from US$ 2447 million in 2025 to US$ 3610 million by 2032, at a CAGR of 6.1% (2026-2032), driven by critical product segments and diverse en... もっと見る

 

 

出版社
QYResearch
QYリサーチ
出版年月
2026年11月15日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報/注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Ruminant Vaccines Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Ruminant Vaccines Market Size Growth Rate by Preventing Disease, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Ruminant Vaccines Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Ruminant Vaccines Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Ruminant Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Ruminant Vaccines Revenue by Region (US$ Million), 2021-2026
Table 7. Global Ruminant Vaccines Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Ruminant Vaccines Revenue by Players (US$ Million), 2021-2026
Table 10. Global Ruminant Vaccines Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Ruminant Vaccines Revenue, 2025
Table 13. Global Ruminant Vaccines Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Ruminant Vaccines Companies Headquarters
Table 15. Global Ruminant Vaccines Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Ruminant Vaccines Revenue by Type (US$ Million), 2021-2026
Table 19. Global Ruminant Vaccines Revenue by Type (US$ Million), 2027-2032
Table 20. Global Ruminant Vaccines Revenue by Preventing Disease (US$ Million), 2021-2026
Table 21. Global Ruminant Vaccines Revenue by Preventing Disease (US$ Million), 2027-2032
Table 22. Global Ruminant Vaccines Revenue by Antigen Combination (US$ Million), 2021-2026
Table 23. Global Ruminant Vaccines Revenue by Antigen Combination (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Ruminant Vaccines Revenue by Application (US$ Million), 2021-2026
Table 26. Global Ruminant Vaccines Revenue by Application (US$ Million), 2027-2032
Table 27. Ruminant Vaccines High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Ruminant Vaccines Growth Accelerators and Market Barriers
Table 31. North America Ruminant Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Ruminant Vaccines Growth Accelerators and Market Barriers
Table 33. Europe Ruminant Vaccines Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Ruminant Vaccines Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Ruminant Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Ruminant Vaccines Investment Opportunities and Key Challenges
Table 37. Central and South America Ruminant Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Ruminant Vaccines Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Ruminant Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health(Merck) Corporation Information
Table 41. MSD Animal Health(Merck) Description and Major Businesses
Table 42. MSD Animal Health(Merck) Product Features and Attributes
Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health(Merck) Ruminant Vaccines SWOT Analysis
Table 48. MSD Animal Health(Merck) Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Ruminant Vaccines SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Ruminant Vaccines SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Ruminant Vaccines SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Ruminant Vaccines SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. Indian Immunologicals Limited Corporation Information
Table 86. Indian Immunologicals Limited Description and Major Businesses
Table 87. Indian Immunologicals Limited Product Features and Attributes
Table 88. Indian Immunologicals Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Indian Immunologicals Limited Recent Developments
Table 90. Cambridge Technologies Corporation Information
Table 91. Cambridge Technologies Description and Major Businesses
Table 92. Cambridge Technologies Product Features and Attributes
Table 93. Cambridge Technologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Cambridge Technologies Recent Developments
Table 95. Bioveta Corporation Information
Table 96. Bioveta Description and Major Businesses
Table 97. Bioveta Product Features and Attributes
Table 98. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Bioveta Recent Developments
Table 100. Virbac Corporation Information
Table 101. Virbac Description and Major Businesses
Table 102. Virbac Product Features and Attributes
Table 103. Virbac Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Virbac Recent Developments
Table 105. CZ Vaccines(Zendal Group) Corporation Information
Table 106. CZ Vaccines(Zendal Group) Description and Major Businesses
Table 107. CZ Vaccines(Zendal Group) Product Features and Attributes
Table 108. CZ Vaccines(Zendal Group) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. CZ Vaccines(Zendal Group) Recent Developments
Table 110. Vaxxinova Corporation Information
Table 111. Vaxxinova Description and Major Businesses
Table 112. Vaxxinova Product Features and Attributes
Table 113. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Vaxxinova Recent Developments
Table 115. Hester Biosciences Corporation Information
Table 116. Hester Biosciences Description and Major Businesses
Table 117. Hester Biosciences Product Features and Attributes
Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hester Biosciences Recent Developments
Table 120. Jinyu Bio-Technology Corporation Information
Table 121. Jinyu Bio-Technology Description and Major Businesses
Table 122. Jinyu Bio-Technology Product Features and Attributes
Table 123. Jinyu Bio-Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Jinyu Bio-Technology Recent Developments
Table 125. CAHIC Corporation Information
Table 126. CAHIC Description and Major Businesses
Table 127. CAHIC Product Features and Attributes
Table 128. CAHIC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. CAHIC Recent Developments
Table 130. TECON Biology Corporation Information
Table 131. TECON Biology Description and Major Businesses
Table 132. TECON Biology Product Features and Attributes
Table 133. TECON Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. TECON Biology Recent Developments
Table 135. Harbin Pharmaceutical Group Corporation Information
Table 136. Harbin Pharmaceutical Group Description and Major Businesses
Table 137. Harbin Pharmaceutical Group Product Features and Attributes
Table 138. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Harbin Pharmaceutical Group Recent Developments
Table 140. China Agricultural Vet Biology and Technology Co., LTD Corporation Information
Table 141. China Agricultural Vet Biology and Technology Co., LTD Description and Major Businesses
Table 142. China Agricultural Vet Biology and Technology Co., LTD Product Features and Attributes
Table 143. China Agricultural Vet Biology and Technology Co., LTD Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. China Agricultural Vet Biology and Technology Co., LTD Recent Developments
Table 145. HIPRA Corporation Information
Table 146. HIPRA Description and Major Businesses
Table 147. HIPRA Product Features and Attributes
Table 148. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. HIPRA Recent Developments
Table 150. Syva Corporation Information
Table 151. Syva Description and Major Businesses
Table 152. Syva Product Features and Attributes
Table 153. Syva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Syva Recent Developments
Table 155. Pulike Corporation Information
Table 156. Pulike Description and Major Businesses
Table 157. Pulike Product Features and Attributes
Table 158. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Pulike Recent Developments
Table 160. Shenlian Biomedical Corporation Information
Table 161. Shenlian Biomedical Description and Major Businesses
Table 162. Shenlian Biomedical Product Features and Attributes
Table 163. Shenlian Biomedical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Shenlian Biomedical Recent Developments
Table 165. INNER MONGOLIA BIGVETBIOTECH Corporation Information
Table 166. INNER MONGOLIA BIGVETBIOTECH Description and Major Businesses
Table 167. INNER MONGOLIA BIGVETBIOTECH Product Features and Attributes
Table 168. INNER MONGOLIA BIGVETBIOTECH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. INNER MONGOLIA BIGVETBIOTECH Recent Developments
Table 170. Sinopharm Animal Health Corporation Information
Table 171. Sinopharm Animal Health Description and Major Businesses
Table 172. Sinopharm Animal Health Product Features and Attributes
Table 173. Sinopharm Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Sinopharm Animal Health Recent Developments
Table 175. HVRI Corporation Information
Table 176. HVRI Description and Major Businesses
Table 177. HVRI Product Features and Attributes
Table 178. HVRI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. HVRI Recent Developments
Table 180. Jilin Zhengye Corporation Information
Table 181. Jilin Zhengye Description and Major Businesses
Table 182. Jilin Zhengye Product Features and Attributes
Table 183. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Jilin Zhengye Recent Developments
Table 185. Technologies, Platforms and Infrastructure
Table 186. Distributors List
Table 187. Market Trends and Market Evolution
Table 188. Market Drivers and Opportunities
Table 189. Market Challenges, Risks, and Restraints
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Ruminant Vaccines Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Live Attenuated Vaccine Product Picture
Figure 3. Inactivated Vaccine Product Picture
Figure 4. Others Product Picture
Figure 5. Global Ruminant Vaccines Market Size Growth Rate by Preventing Disease, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Foot-and-Mouth Disease Vaccines Product Picture
Figure 7. Bovine Respiratory Disease Vaccines Product Picture
Figure 8. Clostridial Vaccines Product Picture
Figure 9. Others Product Picture
Figure 10. Global Ruminant Vaccines Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Monovalent Live Vaccines Product Picture
Figure 12. Bivalent Live Vaccines Product Picture
Figure 13. Multivalent Live Vaccines Product Picture
Figure 14. Global Ruminant Vaccines Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Cattle Farming
Figure 16. Sheep Farming
Figure 17. Others
Figure 18. Ruminant Vaccines Report Years Considered
Figure 19. Global Ruminant Vaccines Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 21. Global Ruminant Vaccines Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Ruminant Vaccines Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Ruminant Vaccines Revenue-Based Market Share Ranking (2025)
Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 25. Live Attenuated Vaccine Revenue-Based Market Share by Player in 2025
Figure 26. Inactivated Vaccine Revenue-Based Market Share by Player in 2025
Figure 27. Others Revenue-Based Market Share by Player in 2025
Figure 28. Global Ruminant Vaccines Revenue-Based Market Share by Type (2021-2032)
Figure 29. Global Ruminant Vaccines Revenue-Based Market Share by Preventing Disease (2021-2032)
Figure 30. Global Ruminant Vaccines Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 31. Global Ruminant Vaccines Revenue-Based Market Share by Application (2021-2032)
Figure 32. North America Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 33. North America Top 5 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 34. North America Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 35. US Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 36. Canada Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 37. Mexico Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 38. Europe Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 39. Europe Top 5 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 40. Europe Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 41. Germany Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 42. France Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 43. U.K. Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 44. Italy Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 45. Russia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 46. Asia-Pacific Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 47. Asia-Pacific Top 8 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 48. Asia-Pacific Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 49. Indonesia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 50. Japan Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 51. South Korea Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 52. Australia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 53. India Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 54. Indonesia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 55. Vietnam Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 56. Malaysia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 57. Philippines Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 58. Singapore Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 59. Central and South America Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 60. Central and South America Top 5 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 61. Central and South America Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 62. Brazil Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 63. Argentina Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 64. Middle East and Africa Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 65. Middle East and Africa Top 5 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 66. Middle East and Africa Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 67. GCC Countries Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 68. Israel Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 69. Egypt Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 70. South Africa Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 71. Ruminant Vaccines Value Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

 

ページTOPに戻る


 

Summary

The global Ruminant Vaccines market is projected to grow from US$ 2447 million in 2025 to US$ 3610 million by 2032, at a CAGR of 6.1% (2026-2032), driven by critical product segments and diverse end‑use applications.

Ruminant Vaccines are veterinary biological products used for active immunization and herd-level prevention of infectious diseases in cattle, sheep, goats, buffaloes, and other ruminants. They induce specific humoral, cellular, or mucosal immunity by introducing live attenuated pathogens, inactivated pathogens, bacterial toxoids, recombinant antigens, or other immunogenic biological components. By vaccine type, the product is divided into Live Attenuated Vaccines, Inactivated Vaccines, and Others; by Preventing Disease, into Foot-and-Mouth Disease Vaccines, Bovine Respiratory Disease Vaccines, Clostridial Vaccines, and Others; and by Antigen Combination, into Monovalent Live Vaccines, Bivalent Live Vaccines, and Multivalent Live Vaccines. Major formulations include lyophilized live vaccines, liquid inactivated vaccines, oil emulsions, aluminum-adjuvanted vaccines, and toxoid formulations and are mainly administered by subcutaneous, intramuscular, or intranasal routes.

Key Findings
The average industry gross margin in 2025 is approximately 40%–60%.

Inactivated Vaccines represent the largest value segment, with standard commercial Foot-and-Mouth Disease vaccines providing ≥3 PD50 per dose and high-potency emergency vaccines providing ≥6 PD50 per dose.

Cattle Farming represents the largest downstream application.

Zoetis, MSD Animal Health, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health are positioned among the leading global suppliers.

Market Trends
The product is evolving from conventional single-disease vaccines toward multivalent combinations, highly purified antigens, advanced adjuvants, DIVA differentiation, and precision immunization. Foot-and-Mouth Disease remains centered on inactivated technology because live-virus vaccines are not accepted due to the risk of reversion to virulence, making high potency, multiserotype matching, and non-structural-protein purification important development routes. Bovine Respiratory Disease portfolios continue to combine IBR, BVD, PI3, BRSV, and bacterial antigens, with some commercial products already covering more than ten respiratory and reproductive antigens. At the same time, emerging or re-emerging regional diseases such as Bluetongue BTV-3 are driving new vaccine introductions for cattle and sheep. Future development will increasingly focus on fewer injections, longer protection, and digital herd-vaccination management.

Market Dynamics
Drivers
Demand for the product is mainly driven by large-scale cattle and sheep farming, continuous control of major livestock diseases, management of respiratory disease in calves, and prevention of clostridial disease in lambs. FMD control in endemic regions requires high levels of population immunity, and WOAH recommends at least 80% vaccination coverage in target populations together with appropriate antigenic matching between vaccine and circulating strains. Bovine Respiratory Disease broadly affects beef calves, dairy calves, and feedlot cattle, encouraging vaccination before weaning, movement, and feedlot entry. Sheep production also has stable demand for vaccination against enterotoxemia, blackleg, tetanus, and other clostridial diseases across breeding, growing, and production stages.

Restraints
The main restraints include dependence on cold-chain management, complex vaccination schedules, regional differences in disease epidemiology, and safety requirements that vary across vaccine technologies. Certain modified-live respiratory vaccines have specific restrictions in pregnant cattle and animals that have not completed appropriate priming, requiring strict label-based use. Inactivated Vaccines generally have broader safety margins but commonly require a two-dose primary course followed by boosters. Foot-and-Mouth Disease also involves multiple serotypes and extensive antigenic variation, with limited reliable cross-protection between serotypes, requiring continuous matching to regional field strains. Freezing of adjuvanted emulsions, breaks in cold-chain handling, and incorrect field dosage can also reduce vaccine performance.

Opportunities
Future opportunities are concentrated in Multivalent Vaccines, DIVA technologies, high-potency FMD antigens, advanced Bovine Respiratory Disease combinations, and vaccines against emerging vector-borne diseases. Standard FMD vaccines generally provide ≥3 PD50 per dose, while emergency or high-risk programs may use ≥6 PD50 products. Ceva's Aftomune uses the bivalent inactivated O1 Campos and A24 Cruzeiro antigens at a 2 mL dose for cattle and buffaloes. Respiratory vaccines are expanding from conventional four- or five-way products toward combined viral and bacterial coverage, while emerging Bluetongue BTV-3 circulation has created additional demand. Low-volume administration, longer-duration protection, broad multi-disease coverage, and products that support differentiation of infected from vaccinated animals are likely to capture greater value.

Challenges
The core challenges are stable antigenic matching, broad cross-protection, long-term safety, and batch consistency. Foot-and-Mouth Disease virus has multiple serotypes and numerous antigenic variants, and poor matching between vaccine and circulating field strains can substantially reduce practical protection, requiring continuous antigenic matching and surveillance. Bovine Respiratory Disease is multifactorial and involves viruses, bacteria, stress, and environmental factors, so vaccination cannot replace ventilation, nutrition, and biosecurity. Multivalent products can reduce handling but may introduce antigenic interference and therefore require optimized antigen loads, adjuvants, and administration schedules. For sheep, clostridial vaccination also needs to be coordinated with vaccination of pregnant ewes and colostrum management to maximize early passive protection in lambs.

Industry Chain Analysis
The upstream supply chain mainly includes master and working seed strains, BHK and other animal cell lines, cell-culture media, bacterial fermentation substrates, inactivating agents, adjuvants, stabilizers, lyophilization protectants, culture consumables, glass vials, and cold-chain packaging. Seed purity, cell-substrate safety, antigen concentration, and adjuvant performance determine fundamental quality. Midstream operations include viral or bacterial propagation, antigen harvesting, concentration and purification, attenuation or inactivation, toxoid preparation, antigen quantification, adjuvant emulsification, aseptic filling, potency and safety testing, and batch release. A representative inactivated FMD product uses BHK21 cells for virus propagation, followed by BEI inactivation, purification, concentration, and oil-adjuvant emulsification. Downstream demand comes from Cattle Farming, Sheep Farming, and Other ruminants such as goats and buffaloes through integrated farms, veterinary distribution, government disease-control procurement, and veterinary service channels, supported by cold-chain logistics, serological monitoring, vaccination-program design, and herd-health management.

Segment Insights
By vaccine type and disease, Inactivated Vaccines are estimated to represent the largest value segment, with Foot-and-Mouth Disease being a representative mass-vaccination application. Standard commercial FMD vaccines generally provide at least 3 PD50 per dose, while high-potency emergency products may provide ≥6 PD50 per dose, and live FMD vaccines are not accepted because of reversion-to-virulence risk. Bovine Respiratory Disease uses both Live Attenuated and Inactivated technologies; BOVILIS VISTA products cover IBR, BVD Types 1 and 2, PI3, and BRSV with a typical 2 mL dose. Clostridial products are primarily multivalent inactivated toxoid formulations; Coglavax is used in cattle, sheep, and goats at 2 mL for small ruminants and cattle below 100 kg and 4 mL for cattle above 100 kg.

By Antigen Combination, Monovalent Live Vaccines are primarily used for targeted control of one pathogen or diseases with clearly defined regional epidemiology; Bivalent Live Vaccines simultaneously cover two pathogens or strains and reduce handling; and Multivalent Live Vaccines are increasingly important in respiratory and reproductive disease programs requiring simultaneous control of multiple pathogens. Zoetis Bovi-Shield GOLD 5 represents a typical multivalent modified-live approach covering IBR, BVD 1a/1b/2, PI3, and BRSV. Emerging technologies use recombinant antigens, highly purified toxoids, improved adjuvants, and lower-volume delivery to improve the stability of multi-antigen systems. The technical direction is shifting from single-antigen protection toward integrated programs covering multiple viral, bacterial, and reproductive pathogens.

Downstream Market Opportunities
Cattle Farming represents the largest end-use market. Beef calves and feedlot cattle place strong emphasis on Bovine Respiratory Disease, Clostridial Disease, and FMD prevention, while dairy cattle require additional coverage for reproductive disease and calf enteric disease. Sheep Farming focuses on clostridial disease, tetanus, bluetongue, and FMD, while vaccination of pregnant ewes is used to increase colostral antibody protection for lambs. Other applications include goats and buffaloes; Ceva Coglavax, for example, is approved for cattle, sheep, and goats. Artificial intelligence is not part of the vaccine itself, but electronic ear tags, body temperature, feed intake, activity, cough monitoring, reproductive records, and regional outbreak data can be integrated to identify high-risk animals, optimize booster timing, and recommend disease combinations, supporting a transition from fixed schedules to risk-based precision vaccination.

Regional Insights
North America is a high-value market for Bovine Respiratory Disease, multivalent Clostridial, and reproductive vaccines, with Zoetis, MSD Animal Health, Boehringer Ingelheim, and Elanco maintaining broad cattle portfolios, while routine FMD vaccination is not used in FMD-free markets such as the United States. Europe has mature cattle and sheep vaccine regulation and veterinary infrastructure, and recent BTV-3 Bluetongue outbreaks have driven adoption of new inactivated cattle-and-sheep vaccines. Parts of Asia, Africa, and South America continue to conduct large-scale FMD vaccination programs, where government procurement and high-coverage population vaccination play important roles. China and India have large cattle and sheep populations and established domestic animal-vaccine industries, with Jinyu Bio-Technology, CAHIC, TECON Biology, Pulike, Shenlian Biomedical, and Sinopharm Animal Health among regional participants.

Competitive Landscape Analysis
The product market has substantial barriers in seed-strain resources, biological production facilities, cell culture, clinical validation, regulatory approval, and cold-chain services. Representative leading players include Zoetis, MSD Animal Health (Merck), Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health. Zoetis maintains broad multivalent modified-live cattle respiratory portfolios such as Bovi-Shield. MSD uses BOVILIS/VISTA and related platforms across Bovine Respiratory Disease and other ruminant applications. Boehringer Ingelheim maintains strong respiratory and Bluetongue vaccine capabilities. Ceva offers Aftomune, Coglavax, Coxevac, and Bluevac products covering FMD, Clostridial Disease, Q Fever, and Bluetongue. Elanco combines Live Attenuated, Inactivated, and multi-antigen cattle products through NUPLURA, Titanium, and Vira Shield. Competition is shifting from basic antigen supply toward multivalent breadth, duration of protection, DIVA capability, advanced adjuvants, farm technical support, and digital disease-management services.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Ruminant Vaccines market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
MSD Animal Health(Merck)
Zoetis
Boehringer Ingelheim
Ceva Santé Animale
Elanco Animal Health
Indian Immunologicals Limited
Cambridge Technologies
Bioveta
Virbac
CZ Vaccines(Zendal Group)
Vaxxinova
Hester Biosciences
Jinyu Bio-Technology
CAHIC
TECON Biology
Harbin Pharmaceutical Group
China Agricultural Vet Biology and Technology Co., LTD
HIPRA
Syva
Pulike
Shenlian Biomedical
INNER MONGOLIA BIGVETBIOTECH
Sinopharm Animal Health
HVRI
Jilin Zhengye

Segment by Type
Live Attenuated Vaccine
Inactivated Vaccine
Others

Segment by Preventing Disease
Foot-and-Mouth Disease Vaccines
Bovine Respiratory Disease Vaccines
Clostridial Vaccines
Others

Segment by Antigen Combination
Monovalent Live Vaccines
Bivalent Live Vaccines
Multivalent Live Vaccines

Segment by Application
Cattle Farming
Sheep Farming
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Ruminant Vaccines study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Ruminant Vaccines: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Ruminant Vaccines Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Live Attenuated Vaccine
1.2.3 Inactivated Vaccine
1.2.4 Others
1.3 Market Segmentation by Preventing Disease
1.3.1 Global Ruminant Vaccines Market Size by Preventing Disease, 2021 vs 2025 vs 2032
1.3.2 Foot-and-Mouth Disease Vaccines
1.3.3 Bovine Respiratory Disease Vaccines
1.3.4 Clostridial Vaccines
1.3.5 Others
1.4 Market Segmentation by Antigen Combination
1.4.1 Global Ruminant Vaccines Market Size by Antigen Combination, 2021 vs 2025 vs 2032
1.4.2 Monovalent Live Vaccines
1.4.3 Bivalent Live Vaccines
1.4.4 Multivalent Live Vaccines
1.5 Market Segmentation by Application
1.5.1 Global Ruminant Vaccines Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Cattle Farming
1.5.3 Sheep Farming
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Ruminant Vaccines Revenue Estimates and Forecasts (2021-2032)
2.2 Global Ruminant Vaccines Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Ruminant Vaccines Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Ruminant Vaccines Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Live Attenuated Vaccine: Market Share by Key Players
3.3.2 Inactivated Vaccine: Market Share by Key Players
3.3.3 Others: Market Share by Key Players
3.4 Global Ruminant Vaccines Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Ruminant Vaccines Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Ruminant Vaccines Market by Preventing Disease
4.2.1 Global Revenue by Preventing Disease (2021-2032)
4.2.2 Global Revenue-Based Market Share by Preventing Disease (2021-2032)
4.3 Global Ruminant Vaccines Market by Antigen Combination
4.3.1 Global Revenue by Antigen Combination (2021-2032)
4.3.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Ruminant Vaccines Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Ruminant Vaccines Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Ruminant Vaccines Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Ruminant Vaccines Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Ruminant Vaccines Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Ruminant Vaccines Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Ruminant Vaccines Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Ruminant Vaccines Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Ruminant Vaccines Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Ruminant Vaccines Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Ruminant Vaccines Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 MSD Animal Health(Merck)
11.1.1 MSD Animal Health(Merck) Corporation Information
11.1.2 MSD Animal Health(Merck) Business Overview
11.1.3 MSD Animal Health(Merck) Ruminant Vaccines Product Features and Attributes
11.1.4 MSD Animal Health(Merck) Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.1.5 MSD Animal Health(Merck) Ruminant Vaccines Revenue by Product in 2025
11.1.6 MSD Animal Health(Merck) Ruminant Vaccines Revenue by Application in 2025
11.1.7 MSD Animal Health(Merck) Ruminant Vaccines Revenue by Geographic Area in 2025
11.1.8 MSD Animal Health(Merck) Ruminant Vaccines SWOT Analysis
11.1.9 MSD Animal Health(Merck) Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Ruminant Vaccines Product Features and Attributes
11.2.4 Zoetis Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.2.5 Zoetis Ruminant Vaccines Revenue by Product in 2025
11.2.6 Zoetis Ruminant Vaccines Revenue by Application in 2025
11.2.7 Zoetis Ruminant Vaccines Revenue by Geographic Area in 2025
11.2.8 Zoetis Ruminant Vaccines SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Ruminant Vaccines Product Features and Attributes
11.3.4 Boehringer Ingelheim Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Ruminant Vaccines Revenue by Product in 2025
11.3.6 Boehringer Ingelheim Ruminant Vaccines Revenue by Application in 2025
11.3.7 Boehringer Ingelheim Ruminant Vaccines Revenue by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Ruminant Vaccines SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva Santé Animale
11.4.1 Ceva Santé Animale Corporation Information
11.4.2 Ceva Santé Animale Business Overview
11.4.3 Ceva Santé Animale Ruminant Vaccines Product Features and Attributes
11.4.4 Ceva Santé Animale Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Santé Animale Ruminant Vaccines Revenue by Product in 2025
11.4.6 Ceva Santé Animale Ruminant Vaccines Revenue by Application in 2025
11.4.7 Ceva Santé Animale Ruminant Vaccines Revenue by Geographic Area in 2025
11.4.8 Ceva Santé Animale Ruminant Vaccines SWOT Analysis
11.4.9 Ceva Santé Animale Recent Developments
11.5 Elanco Animal Health
11.5.1 Elanco Animal Health Corporation Information
11.5.2 Elanco Animal Health Business Overview
11.5.3 Elanco Animal Health Ruminant Vaccines Product Features and Attributes
11.5.4 Elanco Animal Health Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.5.5 Elanco Animal Health Ruminant Vaccines Revenue by Product in 2025
11.5.6 Elanco Animal Health Ruminant Vaccines Revenue by Application in 2025
11.5.7 Elanco Animal Health Ruminant Vaccines Revenue by Geographic Area in 2025
11.5.8 Elanco Animal Health Ruminant Vaccines SWOT Analysis
11.5.9 Elanco Animal Health Recent Developments
11.6 Indian Immunologicals Limited
11.6.1 Indian Immunologicals Limited Corporation Information
11.6.2 Indian Immunologicals Limited Business Overview
11.6.3 Indian Immunologicals Limited Ruminant Vaccines Product Features and Attributes
11.6.4 Indian Immunologicals Limited Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.6.5 Indian Immunologicals Limited Recent Developments
11.7 Cambridge Technologies
11.7.1 Cambridge Technologies Corporation Information
11.7.2 Cambridge Technologies Business Overview
11.7.3 Cambridge Technologies Ruminant Vaccines Product Features and Attributes
11.7.4 Cambridge Technologies Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.7.5 Cambridge Technologies Recent Developments
11.8 Bioveta
11.8.1 Bioveta Corporation Information
11.8.2 Bioveta Business Overview
11.8.3 Bioveta Ruminant Vaccines Product Features and Attributes
11.8.4 Bioveta Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.8.5 Bioveta Recent Developments
11.9 Virbac
11.9.1 Virbac Corporation Information
11.9.2 Virbac Business Overview
11.9.3 Virbac Ruminant Vaccines Product Features and Attributes
11.9.4 Virbac Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.9.5 Virbac Recent Developments
11.10 CZ Vaccines(Zendal Group)
11.10.1 CZ Vaccines(Zendal Group) Corporation Information
11.10.2 CZ Vaccines(Zendal Group) Business Overview
11.10.3 CZ Vaccines(Zendal Group) Ruminant Vaccines Product Features and Attributes
11.10.4 CZ Vaccines(Zendal Group) Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Vaxxinova
11.11.1 Vaxxinova Corporation Information
11.11.2 Vaxxinova Business Overview
11.11.3 Vaxxinova Ruminant Vaccines Product Features and Attributes
11.11.4 Vaxxinova Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.11.5 Vaxxinova Recent Developments
11.12 Hester Biosciences
11.12.1 Hester Biosciences Corporation Information
11.12.2 Hester Biosciences Business Overview
11.12.3 Hester Biosciences Ruminant Vaccines Product Features and Attributes
11.12.4 Hester Biosciences Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.12.5 Hester Biosciences Recent Developments
11.13 Jinyu Bio-Technology
11.13.1 Jinyu Bio-Technology Corporation Information
11.13.2 Jinyu Bio-Technology Business Overview
11.13.3 Jinyu Bio-Technology Ruminant Vaccines Product Features and Attributes
11.13.4 Jinyu Bio-Technology Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.13.5 Jinyu Bio-Technology Recent Developments
11.14 CAHIC
11.14.1 CAHIC Corporation Information
11.14.2 CAHIC Business Overview
11.14.3 CAHIC Ruminant Vaccines Product Features and Attributes
11.14.4 CAHIC Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.14.5 CAHIC Recent Developments
11.15 TECON Biology
11.15.1 TECON Biology Corporation Information
11.15.2 TECON Biology Business Overview
11.15.3 TECON Biology Ruminant Vaccines Product Features and Attributes
11.15.4 TECON Biology Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.15.5 TECON Biology Recent Developments
11.16 Harbin Pharmaceutical Group
11.16.1 Harbin Pharmaceutical Group Corporation Information
11.16.2 Harbin Pharmaceutical Group Business Overview
11.16.3 Harbin Pharmaceutical Group Ruminant Vaccines Product Features and Attributes
11.16.4 Harbin Pharmaceutical Group Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.16.5 Harbin Pharmaceutical Group Recent Developments
11.17 China Agricultural Vet Biology and Technology Co., LTD
11.17.1 China Agricultural Vet Biology and Technology Co., LTD Corporation Information
11.17.2 China Agricultural Vet Biology and Technology Co., LTD Business Overview
11.17.3 China Agricultural Vet Biology and Technology Co., LTD Ruminant Vaccines Product Features and Attributes
11.17.4 China Agricultural Vet Biology and Technology Co., LTD Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.17.5 China Agricultural Vet Biology and Technology Co., LTD Recent Developments
11.18 HIPRA
11.18.1 HIPRA Corporation Information
11.18.2 HIPRA Business Overview
11.18.3 HIPRA Ruminant Vaccines Product Features and Attributes
11.18.4 HIPRA Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.18.5 HIPRA Recent Developments
11.19 Syva
11.19.1 Syva Corporation Information
11.19.2 Syva Business Overview
11.19.3 Syva Ruminant Vaccines Product Features and Attributes
11.19.4 Syva Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.19.5 Syva Recent Developments
11.20 Pulike
11.20.1 Pulike Corporation Information
11.20.2 Pulike Business Overview
11.20.3 Pulike Ruminant Vaccines Product Features and Attributes
11.20.4 Pulike Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.20.5 Pulike Recent Developments
11.21 Shenlian Biomedical
11.21.1 Shenlian Biomedical Corporation Information
11.21.2 Shenlian Biomedical Business Overview
11.21.3 Shenlian Biomedical Ruminant Vaccines Product Features and Attributes
11.21.4 Shenlian Biomedical Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.21.5 Shenlian Biomedical Recent Developments
11.22 INNER MONGOLIA BIGVETBIOTECH
11.22.1 INNER MONGOLIA BIGVETBIOTECH Corporation Information
11.22.2 INNER MONGOLIA BIGVETBIOTECH Business Overview
11.22.3 INNER MONGOLIA BIGVETBIOTECH Ruminant Vaccines Product Features and Attributes
11.22.4 INNER MONGOLIA BIGVETBIOTECH Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.22.5 INNER MONGOLIA BIGVETBIOTECH Recent Developments
11.23 Sinopharm Animal Health
11.23.1 Sinopharm Animal Health Corporation Information
11.23.2 Sinopharm Animal Health Business Overview
11.23.3 Sinopharm Animal Health Ruminant Vaccines Product Features and Attributes
11.23.4 Sinopharm Animal Health Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.23.5 Sinopharm Animal Health Recent Developments
11.24 HVRI
11.24.1 HVRI Corporation Information
11.24.2 HVRI Business Overview
11.24.3 HVRI Ruminant Vaccines Product Features and Attributes
11.24.4 HVRI Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.24.5 HVRI Recent Developments
11.25 Jilin Zhengye
11.25.1 Jilin Zhengye Corporation Information
11.25.2 Jilin Zhengye Business Overview
11.25.3 Jilin Zhengye Ruminant Vaccines Product Features and Attributes
11.25.4 Jilin Zhengye Ruminant Vaccines Revenue and Gross Margin (2021-2026)
11.25.5 Jilin Zhengye Recent Developments

12 Ruminant Vaccines Value Chain and Ecosystem Analysis
12.1 Ruminant Vaccines Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Ruminant Vaccines Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Ruminant Vaccines Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Ruminant Vaccines Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Ruminant Vaccines Market Size Growth Rate by Preventing Disease, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Ruminant Vaccines Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Ruminant Vaccines Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Ruminant Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Ruminant Vaccines Revenue by Region (US$ Million), 2021-2026
Table 7. Global Ruminant Vaccines Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Ruminant Vaccines Revenue by Players (US$ Million), 2021-2026
Table 10. Global Ruminant Vaccines Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Ruminant Vaccines Revenue, 2025
Table 13. Global Ruminant Vaccines Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Ruminant Vaccines Companies Headquarters
Table 15. Global Ruminant Vaccines Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Ruminant Vaccines Revenue by Type (US$ Million), 2021-2026
Table 19. Global Ruminant Vaccines Revenue by Type (US$ Million), 2027-2032
Table 20. Global Ruminant Vaccines Revenue by Preventing Disease (US$ Million), 2021-2026
Table 21. Global Ruminant Vaccines Revenue by Preventing Disease (US$ Million), 2027-2032
Table 22. Global Ruminant Vaccines Revenue by Antigen Combination (US$ Million), 2021-2026
Table 23. Global Ruminant Vaccines Revenue by Antigen Combination (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Ruminant Vaccines Revenue by Application (US$ Million), 2021-2026
Table 26. Global Ruminant Vaccines Revenue by Application (US$ Million), 2027-2032
Table 27. Ruminant Vaccines High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Ruminant Vaccines Growth Accelerators and Market Barriers
Table 31. North America Ruminant Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Ruminant Vaccines Growth Accelerators and Market Barriers
Table 33. Europe Ruminant Vaccines Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Ruminant Vaccines Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Ruminant Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Ruminant Vaccines Investment Opportunities and Key Challenges
Table 37. Central and South America Ruminant Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Ruminant Vaccines Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Ruminant Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. MSD Animal Health(Merck) Corporation Information
Table 41. MSD Animal Health(Merck) Description and Major Businesses
Table 42. MSD Animal Health(Merck) Product Features and Attributes
Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025
Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025
Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025
Table 47. MSD Animal Health(Merck) Ruminant Vaccines SWOT Analysis
Table 48. MSD Animal Health(Merck) Recent Developments
Table 49. Zoetis Corporation Information
Table 50. Zoetis Description and Major Businesses
Table 51. Zoetis Product Features and Attributes
Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Zoetis Revenue Proportion by Product in 2025
Table 54. Zoetis Revenue Proportion by Application in 2025
Table 55. Zoetis Revenue Proportion by Geographic Area in 2025
Table 56. Zoetis Ruminant Vaccines SWOT Analysis
Table 57. Zoetis Recent Developments
Table 58. Boehringer Ingelheim Corporation Information
Table 59. Boehringer Ingelheim Description and Major Businesses
Table 60. Boehringer Ingelheim Product Features and Attributes
Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025
Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025
Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025
Table 65. Boehringer Ingelheim Ruminant Vaccines SWOT Analysis
Table 66. Boehringer Ingelheim Recent Developments
Table 67. Ceva Santé Animale Corporation Information
Table 68. Ceva Santé Animale Description and Major Businesses
Table 69. Ceva Santé Animale Product Features and Attributes
Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025
Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025
Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025
Table 74. Ceva Santé Animale Ruminant Vaccines SWOT Analysis
Table 75. Ceva Santé Animale Recent Developments
Table 76. Elanco Animal Health Corporation Information
Table 77. Elanco Animal Health Description and Major Businesses
Table 78. Elanco Animal Health Product Features and Attributes
Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Elanco Animal Health Revenue Proportion by Product in 2025
Table 81. Elanco Animal Health Revenue Proportion by Application in 2025
Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025
Table 83. Elanco Animal Health Ruminant Vaccines SWOT Analysis
Table 84. Elanco Animal Health Recent Developments
Table 85. Indian Immunologicals Limited Corporation Information
Table 86. Indian Immunologicals Limited Description and Major Businesses
Table 87. Indian Immunologicals Limited Product Features and Attributes
Table 88. Indian Immunologicals Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Indian Immunologicals Limited Recent Developments
Table 90. Cambridge Technologies Corporation Information
Table 91. Cambridge Technologies Description and Major Businesses
Table 92. Cambridge Technologies Product Features and Attributes
Table 93. Cambridge Technologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Cambridge Technologies Recent Developments
Table 95. Bioveta Corporation Information
Table 96. Bioveta Description and Major Businesses
Table 97. Bioveta Product Features and Attributes
Table 98. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Bioveta Recent Developments
Table 100. Virbac Corporation Information
Table 101. Virbac Description and Major Businesses
Table 102. Virbac Product Features and Attributes
Table 103. Virbac Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Virbac Recent Developments
Table 105. CZ Vaccines(Zendal Group) Corporation Information
Table 106. CZ Vaccines(Zendal Group) Description and Major Businesses
Table 107. CZ Vaccines(Zendal Group) Product Features and Attributes
Table 108. CZ Vaccines(Zendal Group) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. CZ Vaccines(Zendal Group) Recent Developments
Table 110. Vaxxinova Corporation Information
Table 111. Vaxxinova Description and Major Businesses
Table 112. Vaxxinova Product Features and Attributes
Table 113. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Vaxxinova Recent Developments
Table 115. Hester Biosciences Corporation Information
Table 116. Hester Biosciences Description and Major Businesses
Table 117. Hester Biosciences Product Features and Attributes
Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Hester Biosciences Recent Developments
Table 120. Jinyu Bio-Technology Corporation Information
Table 121. Jinyu Bio-Technology Description and Major Businesses
Table 122. Jinyu Bio-Technology Product Features and Attributes
Table 123. Jinyu Bio-Technology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Jinyu Bio-Technology Recent Developments
Table 125. CAHIC Corporation Information
Table 126. CAHIC Description and Major Businesses
Table 127. CAHIC Product Features and Attributes
Table 128. CAHIC Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. CAHIC Recent Developments
Table 130. TECON Biology Corporation Information
Table 131. TECON Biology Description and Major Businesses
Table 132. TECON Biology Product Features and Attributes
Table 133. TECON Biology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. TECON Biology Recent Developments
Table 135. Harbin Pharmaceutical Group Corporation Information
Table 136. Harbin Pharmaceutical Group Description and Major Businesses
Table 137. Harbin Pharmaceutical Group Product Features and Attributes
Table 138. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Harbin Pharmaceutical Group Recent Developments
Table 140. China Agricultural Vet Biology and Technology Co., LTD Corporation Information
Table 141. China Agricultural Vet Biology and Technology Co., LTD Description and Major Businesses
Table 142. China Agricultural Vet Biology and Technology Co., LTD Product Features and Attributes
Table 143. China Agricultural Vet Biology and Technology Co., LTD Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. China Agricultural Vet Biology and Technology Co., LTD Recent Developments
Table 145. HIPRA Corporation Information
Table 146. HIPRA Description and Major Businesses
Table 147. HIPRA Product Features and Attributes
Table 148. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. HIPRA Recent Developments
Table 150. Syva Corporation Information
Table 151. Syva Description and Major Businesses
Table 152. Syva Product Features and Attributes
Table 153. Syva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Syva Recent Developments
Table 155. Pulike Corporation Information
Table 156. Pulike Description and Major Businesses
Table 157. Pulike Product Features and Attributes
Table 158. Pulike Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Pulike Recent Developments
Table 160. Shenlian Biomedical Corporation Information
Table 161. Shenlian Biomedical Description and Major Businesses
Table 162. Shenlian Biomedical Product Features and Attributes
Table 163. Shenlian Biomedical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Shenlian Biomedical Recent Developments
Table 165. INNER MONGOLIA BIGVETBIOTECH Corporation Information
Table 166. INNER MONGOLIA BIGVETBIOTECH Description and Major Businesses
Table 167. INNER MONGOLIA BIGVETBIOTECH Product Features and Attributes
Table 168. INNER MONGOLIA BIGVETBIOTECH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. INNER MONGOLIA BIGVETBIOTECH Recent Developments
Table 170. Sinopharm Animal Health Corporation Information
Table 171. Sinopharm Animal Health Description and Major Businesses
Table 172. Sinopharm Animal Health Product Features and Attributes
Table 173. Sinopharm Animal Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Sinopharm Animal Health Recent Developments
Table 175. HVRI Corporation Information
Table 176. HVRI Description and Major Businesses
Table 177. HVRI Product Features and Attributes
Table 178. HVRI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. HVRI Recent Developments
Table 180. Jilin Zhengye Corporation Information
Table 181. Jilin Zhengye Description and Major Businesses
Table 182. Jilin Zhengye Product Features and Attributes
Table 183. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Jilin Zhengye Recent Developments
Table 185. Technologies, Platforms and Infrastructure
Table 186. Distributors List
Table 187. Market Trends and Market Evolution
Table 188. Market Drivers and Opportunities
Table 189. Market Challenges, Risks, and Restraints
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Ruminant Vaccines Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Live Attenuated Vaccine Product Picture
Figure 3. Inactivated Vaccine Product Picture
Figure 4. Others Product Picture
Figure 5. Global Ruminant Vaccines Market Size Growth Rate by Preventing Disease, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Foot-and-Mouth Disease Vaccines Product Picture
Figure 7. Bovine Respiratory Disease Vaccines Product Picture
Figure 8. Clostridial Vaccines Product Picture
Figure 9. Others Product Picture
Figure 10. Global Ruminant Vaccines Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Monovalent Live Vaccines Product Picture
Figure 12. Bivalent Live Vaccines Product Picture
Figure 13. Multivalent Live Vaccines Product Picture
Figure 14. Global Ruminant Vaccines Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Cattle Farming
Figure 16. Sheep Farming
Figure 17. Others
Figure 18. Ruminant Vaccines Report Years Considered
Figure 19. Global Ruminant Vaccines Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 21. Global Ruminant Vaccines Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Ruminant Vaccines Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Ruminant Vaccines Revenue-Based Market Share Ranking (2025)
Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 25. Live Attenuated Vaccine Revenue-Based Market Share by Player in 2025
Figure 26. Inactivated Vaccine Revenue-Based Market Share by Player in 2025
Figure 27. Others Revenue-Based Market Share by Player in 2025
Figure 28. Global Ruminant Vaccines Revenue-Based Market Share by Type (2021-2032)
Figure 29. Global Ruminant Vaccines Revenue-Based Market Share by Preventing Disease (2021-2032)
Figure 30. Global Ruminant Vaccines Revenue-Based Market Share by Antigen Combination (2021-2032)
Figure 31. Global Ruminant Vaccines Revenue-Based Market Share by Application (2021-2032)
Figure 32. North America Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 33. North America Top 5 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 34. North America Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 35. US Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 36. Canada Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 37. Mexico Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 38. Europe Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 39. Europe Top 5 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 40. Europe Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 41. Germany Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 42. France Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 43. U.K. Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 44. Italy Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 45. Russia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 46. Asia-Pacific Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 47. Asia-Pacific Top 8 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 48. Asia-Pacific Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 49. Indonesia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 50. Japan Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 51. South Korea Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 52. Australia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 53. India Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 54. Indonesia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 55. Vietnam Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 56. Malaysia Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 57. Philippines Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 58. Singapore Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 59. Central and South America Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 60. Central and South America Top 5 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 61. Central and South America Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 62. Brazil Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 63. Argentina Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 64. Middle East and Africa Ruminant Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 65. Middle East and Africa Top 5 Players Ruminant Vaccines Revenue (US$ Million) in 2025
Figure 66. Middle East and Africa Ruminant Vaccines Revenue (US$ Million) by Application (2021-2032)
Figure 67. GCC Countries Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 68. Israel Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 69. Egypt Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 70. South Africa Ruminant Vaccines Revenue (US$ Million), 2021-2032
Figure 71. Ruminant Vaccines Value Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(vaccines)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/20 10:25

160.51 円

176.53 円

212.83 円

ページTOPに戻る